Sign In
Buy TAK
$15.03
-0.150 (-0.99%)
At Close: Jun 03, 2026
Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological Diseases
12:09pm, Thursday, 18'th Mar 2021
Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-def
Larry Robbins' Firm Buys Into HighCape Capital Acquisition
03:37pm, Tuesday, 16'th Mar 2021
Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.
IDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity
02:00pm, Monday, 15'th Mar 2021
Japan's Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's (NYSE: JNJ) single-dose COVID
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for B
Takeda and IDT Support Manufacturing of Johnson & Johnson's COVID-19 Vaccine
07:30am, Monday, 15'th Mar 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development a
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
02:00am, Friday, 12'th Mar 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Takeda exercised its option to acquire Maverick, expanding its immuno-oncology portfolio with two development candidates and a T-cell engager platform
Finch Therapeutics Takes Flight With IPO Plan
07:05am, Monday, 08'th Mar 2021
Finch Therapeutics Takes Flight With IPO Plan
Moderna, via Takeda, seeks authorization for COVID-19 vaccine in Japan
07:38am, Friday, 05'th Mar 2021
Shares of Moderna Inc. were down 0.9% in premarket trading on Friday after the company said it is pursuing approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. . Ta
Takeda Seeks Approval For Moderna's COVID-19 Shot In Japan
05:46am, Friday, 05'th Mar 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application t
Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan
01:30am, Friday, 05'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
09:37am, Wednesday, 03'rd Mar 2021
Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epilep
The Top New Buys of Larry Robbins' Firm
03:14pm, Friday, 26'th Feb 2021
Glenview Capital Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.
Takeda Divests Four Diabetes Products In Japan To Teijin Pharma
06:26am, Friday, 26'th Feb 2021
Takeda Pharmaceutical Co Ltd (NYSE: TAK) will sell its four non-core type-2 diabetes products (Nesina, Liovel, Inisync, and Zafatek) in Japan to Teijin Pharma Limited, ¥133 billion (roughly $1.2
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
02:00am, Friday, 26'th Feb 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to transfer the assets, marketing righ
